DEPOMED AND KING PHARMACEUTICALS PREPARE FOR LAUNCH OF GLUMETZA AS TIMELY, NEW ADA GUIDELINES ARE ISSUED

Depomed, Inc. and King Pharmaceuticals, Inc. announced that as they prepare for the launch of Glumetza (metformin hydrochloride extended-release tablets), a new consensus statement was issued from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The statement recommends that treatment with metformin be initiated at diagnosis along with lifestyle changes in patients with Type 2 diabetes. In the absence of specific contraindications, metformin is recommended because of its effect on glycemia and absence of weight gain, among other benefits. The consensus statement was published in the August 2006 issue of Diabetes Care.
Genetic Engineering News